

Monthly Market Commentary

August was another buoyant month for global equities, led by the US and Asia. Markets looked past both political pressure on US institutions and a soft jobs report, choosing instead to take comfort in a more dovish Fed, a strong earnings season (81% of S&P500 companies that have so far reported have beaten - reduced - estimates), and progress on trade.

Breadth improved as some of the AI leaders gave back ground. Weak results and intensifying competition from China played a role, but selling pressure also followed an MIT report noting that 95% of firms are seeing no return on their generative AI investment. With hundreds of billions of dollars already committed, the question of incremental returns will remain central for those exposed to the sector.

US large-cap indices again set record highs, with the S&P 500 up 1.9% and the NASDAQ up 1.6%. The real standouts, however, were small caps: the S&P 600 Small Cap Index rose 6.9% in August. Asia also performed strongly. China's Shanghai Composite gained 8%, helped by support for domestic technology leaders, easing geopolitical tensions, and flows from both retail investors and state funds. Japan's Nikkei 225 added 4.0% on reduced tariff concerns and a generally constructive corporate outlook.

Europe was the laggard. Political instability in France and scepticism about its fiscal position drove the CAC 40 down 0.9%, alongside a sharp rise in government bond yields. Germany's DAX slipped 0.7%, with its technology exposure also weighing. The UK's FTSE was the relative bright spot, closing 0.6% higher.

By sector, Materials and Health Care led with gains of 7% and 5%, respectively. Consumer Discretionary, Telecommunications, Energy, and Financials also performed well, each rising more than 3% over the month. Information Technology lagged, finishing only 0.4% higher, while Utilities declined 0.8%.

Against this backdrop the Fund returned +2.17% for the month.

The US Dollar Index (DXY), which measures the dollar against a basket of major currencies, gave up most of last month's gains, falling 2.2% in August amid growing country-specific risks and a softer rate outlook. Yields on US 10-year Treasuries also fell 15bps to 4.23%. Against this backdrop, the AUD rose 2.8% against the USD.

Commodities were mixed, with WTI Oil down 7.6% on rising US crude stocks and weaker demand forecasts, while gold rose 4.8%, helping drive the Bloomberg Commodity Index up 1.6% in August. Reflecting the risk-on tone, the VIX edged lower, closing the month at 15.36, down 1.36 points.

UK-based distributor Bunzl was a key contributor to performance in August. The shares rallied after a well-received H1 2025 result in which management reaffirmed full-year guidance and resumed the buyback. Operational issues are not yet fully behind the group, but early signs are encouraging and the stock continues to enjoy valuation support at around 11.6x EBIT. If management executes successfully, we see scope for the shares to reach roughly £36 over the next few years, implying 34% upside.

In contrast, US-based fertilizer producer CF Industries was the largest detractor. The stock fell after Q2 results missed expectations, largely due to higher SG&A, with weaker farm economics also weighing. Short-term earnings will remain volatile, but the company's strong balance sheet and favourable industry dynamics should support both its next growth phase (BluePoint) and ongoing shareholder returns. With a track record of expanding its cost-advantaged asset base at attractive rates of incremental returns, and trading near 1x EV/Gross Invested Capital, a proxy for replacement cost, we remain comfortable holding the position.

We believe the most compelling way to compound clients' wealth is by utilising multiple return sources to deliver superior risk-adjusted investment outcomes.

- Long-term compounding of investor wealth
- Multiple sources of return
- Quarterly distributions
- Risk focused investment mindset



The investment process behind the Talaria Global Equity Fund Complex ETF takes a high conviction, value biased approach to construct a portfolio of high quality, large cap companies from around the globe. Our unique investment methodology harnesses the benefits of consistent income generation and capital appreciation to grow investors' real wealth.


Performance as at 31 August 2025¹

	1 Month	3 Months	6 Months	1 Year	3 Years (pa)	5 Years (pa)	7 Years (pa)	10 Years (pa)	Since Inception (pa) ²
Total Return	2.17%	1.43%	0.56%	6.90%	10.96%	11.70%	8.25%	7.29%	7.46%
Avg. Market Exposure ⁴	60%	59%	60%	64%	60%	58%	58%	59%	61%

¹ Fund Returns are calculated after fees and expenses and assume the reinvestment of distributions.
² Inception date for performance calculation is 18 August 2008.
³ Past performance is not a reliable indicator of future performance.


⁴ Average Market Exposure calculated on delta-adjusted exposure of underlying portfolio. Since inception market exposure is calculated from September 2008.

Growth of \$10,000 Since Inception⁵



⁵ Calculations are based on exit price, net of management fees and expenses and assumes reinvestment of distributions Past performance is not a reliable indicator of future performance.

Annual Distributions⁶




⁶ Illustrates Distribution Returns for the Talaria Global Equity Fund Complex ETF Units for the financial year ending 30 June 2025. Inception date is 18 August 2008.

Top 10 Holdings⁷

Company Name	Holding	Country	Sector	Description
Newmont	6.3%	USA	Materials	One of the top 3 gold producers in the world
Everest Re	4.8%	USA	Financials	Leading global provider of reinsurance and insurance services
Roche	4.7%	Switzerland	Health Care	A global leader in cancer treatments
Johnson & Johnson	4.7%	USA	Health Care	Pharmaceutical, medical devices and consumer health products company
EOG Resources	3.9%	USA	Energy	One of North America’s largest independent oil and gas producers
Bunzl	3.7%	United Kingdom	Industrials	Multinational distribution and outsourcing business
Essity	3.7%	Sweden	Consumer Staples	A global health and hygiene company based in Sweden
Sanofi	3.7%	France	Health Care	Top 5 pharmaceutical firm with leading positions in diabetes and rare diseases
Bayer	3.4%	Germany	Health Care	Multinational pharmaceutical and life sciences company
Chubb	3.4%	USA	Financials	Global property and casualty insurance company


⁷ Weightings include option positions held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Sector Allocation⁸



^{8,9} Weightings include option positions held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

Regional Allocation⁹



* USA includes American Depositary Receipts (ADRs) listings.

Fund Snapshot

APIR Code	AUS0035AU	Inception Date	18 August 2008
Management Fee	1.16% p.a. of the net asset value of the Fund plus Recoverable Expenses	Liquidity	Daily
Recoverable Expenses	Estimated to be 0.12% of net asset value of the Fund each Financial Year	Exit Price	\$4.94550 (31 Aug 2025)
Major Platform Availability	Asgard, Ausmaq, BT Panorama, BT Wrap, CFS Edge, CFS FirstChoice, Dash, Expand, Hub24, IconIQ, IOOF Pursuit, Linear, Macquarie, Mason Stevens, Netwealth, North, Powerwrap, Praemium	Buy / Sell Spread	0.20% / 0.20%
		Distributions	Quarterly
		Minimum Investment	\$5,000

Important Information

Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298), AFSL 240975, is the Responsible Entity for the Talaria Global Equity Fund Complex ETF ("the Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). This report has been prepared by Talaria Asset Management (Talaria) to provide you with general information only. In preparing this information, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Talaria, Equity Trustees nor any of its related parties, their employees or directors, provide any warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product. Talaria Global Equity Fund Complex ETF's Target Market Determination is available [here](#). A Target Market Determination is a document which is required to be made available from 5 October 2021. It describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed. The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned November 2024 for fund AUS0035AU) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines. The rating issued 04/2025 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit [lonsec.com.au](#) for ratings information and to access the full report. © 2025 Lonsec. All rights reserved. The Genium rating (assigned May 2025) presented in this document is issued by Genium Investment Partners Pty Ltd ABN 15 165 099 785, which is a Corporate Authorised Representative of Genium Advisory Services Pty Ltd ABN 94 304 403 582, AFSL 246580. The Rating is limited to "General Advice" (s766B Corporations Act 2001 (Cth)) and has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without notice. Past performance information is for illustrative purposes only and is not indicative of future performance. It is not a recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision in relation to this financial product(s). Genium receives a fee from the Fund Manager for researching and rating the product(s). Visit [Geniumip.com.au](#) for information regarding Genium's Ratings methodology. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") and is licensed for use by Talaria Asset Management. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

